The management of CIDP is a lifelong journey, often requiring regular infusions that can be physically and logistically demanding for patients with mobility issues. In response, the North American and European markets are leading a move toward "patient-centric" care models that prioritize home-based administration. The development of pre-filled syringes and automated infusion pumps for subcutaneous immunoglobulin has empowered patients to manage their condition with greater independence. This decentralization of care is not only improving patient adherence to long-term treatment plans but is also proving to be a more cost-effective model for insurance payers by reducing the frequency of hospital visits.

Analysis of the Chronic Inflammatory Demyelinating Polyneuropathy Market suggests that the "Homecare Settings" segment is poised for the fastest growth rate among end-users. This trend is supported by the expansion of "tele-neurology" services, which allow specialists to monitor patient progress and adjust dosages remotely. Pharmaceutical companies are increasingly offering "patient support programs" that provide at-home nursing assistance and educational resources, further strengthening the bond between the manufacturer and the end-user. As value-based healthcare becomes the standard, the ability of a therapy to offer both clinical efficacy and lifestyle flexibility is becoming a key determinant of its commercial success.